Fig_2.tif (2.72 MB)

Hr-anxA1 has no significant effect on early plaque development.

figure

posted on 2015-06-19, 04:32 authored by Dennis H. M. Kusters, Martijn L. Chatrou, Brecht A. G. Willems, Marijke De Saint-Hubert, Matthias Bauwens, Emiel van der Vorst, Stefania Bena, Erik A. L. Biessen, Mauro Perretti, Leon J. Schurgers, Chris P. M. Reutelingsperger

12 weeks old mice were fed WTD during 6 weeks. Hr-anxA1 treatment started at start of WTD. (A) Representative H&E staining of aortic arches after 6 weeks of treatment. (B) Treatment with hr-anxA1 did not affect plaque burden in the arch and subclavian (SA) brachiocephalic (BCA) and left common carotid artery (CA). (C) Individual plaque stability and progression was scored on following parameters: neutrophil and macrophage content, apoptosis and necrosis, cap thickness and calcification status (see S1 and S2 Tables). Hr-anxA1 treatment had no effect on early plaque stability and progression. (D, E) Hr-anxA1 treatment had no effect on endothelial ICAM-1 expression of IX and SL lesions. IX: intimal xanthoma; SL: small lesion; IL: intermediate lesion; AL: advanced lesion. All values are represented as mean ±SEM, n = 12 animals per group. Panel A: 40x magnification, scale bar represents 500μm. Panel D: 200x magnification, scale bar represents 100μm.